P27kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells

ASIA unversity > 醫學暨健康學院 > 生物科技學系 > 期刊論文 > Item 310904400/4629

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://asiair.asia.edu.tw/ir/handle/310904400/4629

题名:	P27kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells
作者:	Nahta, R.;Takahahshi, T.;Ueno, N. T.;Mien-Chie Hung;Esteva, F. J.
日期:	2004-06
上传时间:	2009-11-27 13:57:08 (UTC+8)
出版者:	Asia University
摘要:	Trastuzumab (Herceptin) is a recombinant humanized monoclonal antibody directed against HER-2. The objective response rate to trastuzumab monotherapy is 12?34% for a median duration of 9 months, by which point most patients become resistant to treatment. We created two trastuzumab-resistant (TR) pools from the SKBR3 HER-2-overexpressing breast cancer cell line to study the mechanisms by which breast cancer cells escape trastuzumab-mediated growth inhibition. Both pools maintained her-2 gene amplification and protein overexpression. Resistant cells demonstrated a higher S-phase fraction by flow cytometry and a faster doubling time of 24?36 h compared with 72 h for parental cells. The cyclin-dependent kinase inhibitor p27kip1 was decreased in TR cells, and cyclin-dependent kinase 2 activity was increased. Importantly, exogenous addition of p27kip1 increased trastuzumab sensitivity. Additionally, resistant cells displayed heightened sensitivity to the proteasome inhibitor MG132, which induced p27kip1 expression. Thus, we propose that trastuzumab resistance may be associated with decreased p27kip1 levels and may be susceptible to treatments that induce p27kip1 expression.
關聯:	CANCER RESEARCH 64(-):3981-3986
显示于类别:	[生物科技學系] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
		0Kb	Unknown	488	检视/开启
310904400-4629.doc		34Kb	Microsoft Word	455	检视/开启

在ASIAIR中所有的数据项都受到原著作权保护.

数据加载中.....